Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3, Clinical Study of QLG2198 in Haemodialysis Adult Subjects With Moderate-to-Severe Pruritus

NCT06446310 is registered in ClinicalTrials.gov with Qilu Pharmaceutical (Hainan) Co., Ltd. as lead sponsor.

NCT NCT06446310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06446310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3, Clinical Study of QLG2198 in Haemodialysis Adult Subjects With Moderate-to-Severe Pruritus
Lead sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
June 18, 2024
Completion date
August 3, 2025
Enrollment
194 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

uremic pruritus